FREMONT, Calif., April 26, 2016 /PRNewswire/ -- Asterias
Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company with
three clinical-stage development programs focused on the emerging
field of regenerative medicine, today announced that Katharine Spink, Ph.D., Chief Operating Officer,
will present at the Stem Cell Summit 2016 to be held on
April 25-27, 2016 in Boston, MA. Dr. Spink will provide an overview
of the Asterias AST-OPC1 (oligodendrocyte progenitor cells)
therapeutic development program that is currently in a Phase 1/2a
dose escalation clinical trial in spinal cord injury.
Presentation
Details
|
|
|
Event:
|
Stem Cell Summit
2016
|
|
Conference 2: Stem
Cell Product Development & Commercialization
|
|
|
Date:
|
Wednesday, April 27,
2016
|
|
|
Time:
|
9:40 a.m.
EDT
|
|
|
Location:
|
Hyatt Regency,
Boston, MA
|
The title of Dr. Spink's presentation is "AST-OPC1: Clinical
Development of a Novel Cellular Therapeutic for Spinal Cord
Injury." The presentation will be available on Asterias' website at
www.asteriasbiotherapeutics.com.
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a leading biotechnology
company in the emerging field of regenerative medicine. The
company's proprietary cell therapy programs are based on its
immunotherapy and pluripotent stem cell platform
technologies. Asterias is presently focused on advancing
three clinical-stage programs which have the potential to address
areas of very high unmet medical need in the fields of oncology and
neurology. AST-VAC1 (antigen-presenting autologous dendritic cells)
demonstrated promise in a Phase 2 study in acute myelogenous
leukemia (AML) and completed a successful end-of-Phase 2 meeting
with the FDA in advance of initiating planning for a single pivotal
Phase 3 AML study. AST-VAC2 (antigen-presenting allogeneic
dendritic cells) represents a second generation, allogeneic
immunotherapy. The company's research partner, Cancer Research UK,
plans to begin a Phase 1/2 clinical trial of AST-VAC2 in non-small
cell lung cancer in 2017. AST-OPC1 (oligodendrocyte
progenitor cells) is currently in a Phase 1/2a dose escalation
clinical trial in spinal cord injury. Additional information about
Asterias can be found at www.asteriasbiotherapeutics.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/asterias-biotherapeutics-to-present-at-stem-cell-summit-2016-300257015.html
SOURCE Asterias Biotherapeutics, Inc.